The DZHK-funded TRICI-HF-DZHK24 study investigated whether transcatheter tricuspid-valve repair improves outcomes in patients with symptomatic severe tricuspid regurgitation and an increased risk of heart-failure events.
Compared with medical therapy alone, transcatheter repair plus medical therapy improved the combined outcome of survival, heart-failure hospitalization and quality of life at one year. Over three years, it was also associated with a substantially lower risk of death or hospitalization for heart failure.
For patients, this means that transcatheter tricuspid-valve repair may offer a treatment option that not only improves quality of life but can also reduce the risk of hospitalization and death.
Link to publication:
Hausleiter J, Stocker TJ, Geisler T, et al. Tricuspid-Valve Intervention in Heart Failure. N Engl J Med. 2026;395(14):1363-1373. doi:10.1056/NEJMoa2606934
Link to press release:
Minimally Invasive Tricuspid Valve Repair Reduces Mortality and Hospitalisations
